Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology

1 Jan 2020

Abstract excerpt

INTRODUCTION: Adults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and suggest targets for disease modifying treatments. METHODS: We describe the development of a multi-center, longitudinal study of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Down syndrome and intellectual disability research
Share to Genetic Neurodegenerative Diseases
Share to Signaling Pathways in Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32775597
DOI: 10.1002/dad2.12065

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodologyPMID 32775597Read ↗

Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer’s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) StudySemantic proximity Read ↗

The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome: A decade of discoverySemantic proximity Read ↗

AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndromeSemantic proximity Read ↗

Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome.Semantic proximity Read ↗

Genome-wide association analyses identify candidate loci for amyloid imaging and plasma biomarkers in adults with Down syndrome.Semantic proximity Read ↗

Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down SyndromeSemantic proximity Read ↗

Aging with Down Syndrome—Where Are We Now and Where Are We Going?Semantic proximity Read ↗

Risk of Alzheimer's disease in Down syndrome: Insights gained by multi‐omicsSemantic proximity Read ↗

Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.Semantic proximity Read ↗

Aging in Down Syndrome and the Development of Alzheimer's Disease NeuropathologySemantic proximity Read ↗

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional studySemantic proximity Read ↗

From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approachSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.